JPM

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2001, for J.P. Morgan Chase & Co. The reporting period reflects the combined results of The Chase Manhattan Corporation and J.P. Morgan & Co. Incorporated following their merger on December 31, 2000, which was accounted for as a pooling of interests. The firm operates through five major segments: Investment Bank, Investment Management & Private Banking, Treasury & Securities Services, JPMorgan Partners, and Retail & Middle Market Financial Services.

Key Financial Metrics

Cash Flow: Net cash used in operating activities was $10.4 billion, primarily driven by changes in trading-related assets and liabilities. Net cash provided by investing activities was $1.7 billion, and financing activities provided $7.1 billion.

Material Changes vs. Prior Period

• Revenue Decline: Total net revenue decreased 7% year-over-year to $7.8 billion. This was driven by a 21% drop in investment banking fees due to weak equity capital markets and M&A activity, and a significant swing in private equity results.
• Profitability Drop: Net income fell 40% to $1.2 billion. Diluted earnings per share declined 43% to $0.58.
• Private Equity Volatility: JPMorgan Partners reported net private equity gains of $132 million, a sharp decrease from $674 million in Q1 2000. This was due to $285 million in unrealized losses offsetting $412 million in realized gains.
• Expense Management: Total noninterest expense increased 11% to $5.9 billion, largely due to $328 million in merger and restructuring costs and higher amortization of intangibles ($177 million vs. $93 million). On a cash operating basis, expenses declined 5% compared to pro forma Q1 2000.
• Credit Costs: The provision for loan losses increased 31% to $447 million, reflecting higher charge-offs in the commercial loan portfolio. Nonperforming assets rose to $2.23 billion from $1.92 billion at year-end 2000.

Guidance, Outlook, and Risks

• Accounting Change (SFAS 133): The adoption of SFAS 133 (Accounting for Derivative Instruments) resulted in a one-time after-tax reduction to net income of $25 million. Management anticipates this may cause increased volatility in future quarterly earnings and equity due to hedge ineffectiveness and changes in hedging strategies.
• Merger Synergies: Management anticipates that revenue synergies from the Chase/J.P. Morgan merger for the full year 2001 will likely be lower than previously estimated if M&A and equity underwriting activity remains at Q1 2001 levels.
• Outlook: Management expects commercial net charge-off rates for 2001 to fall within a targeted range of 40-60 basis points. Credit card net charge-off ratios are expected to be comparable to 2000, though total charge-off amounts may increase. Management targets full-year 2001 cash operating expenses to be lower than pro forma 2000 levels.
• Risks: Key risks include continued volatility in the public equities market affecting JPMorgan Partners' unrealized valuations, challenging credit conditions in the U.S. commercial sector, and potential legal liabilities from pending litigation (e.g., Sumitomo Corporation, CFS asset-backed securities).

Investor Verification Checklist

• Private Equity Valuations: Verify the composition of the $285 million unrealized loss in JPMorgan Partners, specifically the exposure to telecommunications and technology sectors.
• Merger Integration Costs: Confirm the trajectory of the $328 million in Q1 restructuring costs and the remaining liability balance of $755 million.
• Credit Quality Trends: Monitor the increase in domestic commercial nonperforming loans ($720 million increase vs. prior year) and the specific drivers of the three large domestic commercial credits mentioned.
• SFAS 133 Impact: Assess the potential for future earnings volatility resulting from the new derivative accounting standards and the decision to discontinue certain hedge accounting designations.
• Legal Contingencies: Review the status of the Sumitomo Corporation lawsuits (alleged damages of $532M and $735M) and the CFS-related litigation ($1.2B alleged damages).